Affordable Stock Selections Under $100: Three Wise Investment Choices Presently Available
In the dynamic world of healthcare and pharmaceuticals, three companies are standing out as "no-brainer" stocks for investors seeking strong financial performance and promising growth prospects. These companies are AstraZeneca, Exelixis, and Pfizer, all of which trade under the $100 mark.
Starting with AstraZeneca (AZN), the company reported a solid Q1 2025 with a 7% year-over-year increase in revenue to $13.6 billion, accompanied by a 21% surge in earnings per share to $2.49. The British-Swedish multinational's robust pipeline, which includes nearly 200 programs, positions it well to overcome patent cliffs. Notably, AstraZeneca's shares trade at a forward price-to-earnings ratio of 16.3, almost identical to the healthcare industry's average of 16.2, making it attractively priced given its fundamentals.
Exelixis (EXEL), an oncology company, has been another standout performer. The company's top drug, Cabometyx, has driven the majority of its revenue growth, contributing to a 36% increase in revenue to $513.3 million in Q1 2025. The strong results from Cabometyx have led Exelixis to boost its revenue guidance for the year by $100 million. Exelixis stock is currently trading at 19 times trailing earnings, and it has already risen more than 25% year to date.
Exelixis' success story is not limited to Cabometyx. The company is also involved in multiple late-stage trials with another promising drug, zanzalintinib, for colorectal cancer. Moreover, Exelixis has recorded an impressive 28% profit margin over the trailing 12 months, and it is transitioning from clinical-stage risk to commercial success, as operating income surged 200% to $187 million, and net income tripled to $160 million in Q1 2025.
Pfizer, while not specifically highlighted in the current search results, is typically classified alongside these firms for its strong position in the metastatic prostate cancer market and ongoing innovation in hormonal therapies, chemotherapy, radiopharmaceuticals, and immunotherapies. Pfizer's inclusion is supported by its strategic collaborations and industry leadership in cancer therapeutics, driving long-term prospects. Pfizer's forward dividend yield is over 7%, making it an attractive option for income-focused investors.
In conclusion, these three companies – AstraZeneca, Exelixis, and Pfizer – combine strong earnings growth, pipeline catalysts, reasonable valuations, and expanding market opportunities, making them attractive "no-brainer" buys under $100 in mid-2025. David Jagielski, an analyst, believes that Exelixis can still be a no-brainer buy for investors looking for a good growth stock to hold for the long term. As always, it's essential to conduct thorough research and consider individual investment goals before making any investment decisions.
In the realm of finance and investing, AstraZeneca, with its Q1 2025 revenue of $13.6 billion and a 21% increase in earnings per share, is a promising stock for investors seeking strong financial performance. Exelixis, expanding its revenue by 36% with Cabometyx and flourishing in late-stage trials for zanzalintinib, offers growth prospects and stands as a no-brainer for investors seeking a good long-term growth stock, as echoed by analyst David Jagielski. Pfizer, despite not being specifically highlighted, maintains a strong position in the metastatic prostate cancer market and offers an attractive forward dividend yield of over 7%, making it a compelling choice for income-focused investors.
